Articles tagged with Ebola Virus
Boston University researchers developed a simple diagnostic tool that can quickly identify Ebola and Marburg viruses in blood samples. The biosensor is ultra-portable, fast, and can detect viruses with little to no sample preparation.
Researchers developed novel antisense therapies that protected monkeys infected with deadly Ebola or Marburg viruses, with survival rates over 90%. The treatments were administered up to one hour after exposure and showed promise for treating accidental infections in laboratory or hospital settings.
In a study of rhesus macaques, the experimental Marburg vaccine showed 100% protection when administered 24 hours after lethal exposure, and 66.7% survival rate when treated 48 hours post-infection. The vaccine works by activating the immune system to fight off the target virus.
Scientists have successfully prevented monkeys exposed to the deadly Ebola virus from dying of hemorrhagic fever using a genetic material-based treatment. The study suggests that such protection could also be possible in humans, offering new hope for combating the highly contagious and lethal disease.
A newly developed experimental Ebola vaccine has shown protection in monkeys against a newer Ebola virus species identified in 2007. The vaccine induces a robust T-cell response that can cross-react with other Ebola virus species.
Researchers discovered that the Ebola virus uses a protein called VP35 to mask its RNA, evading the host cell's immune response. This unique mechanism makes Ebola highly deadly and difficult to treat.
Scripps Research scientists have determined the structure of the Ebola virus's critical protein VP35, which blocks the human immune system. The discovery may lead to new drug therapies and vaccines for Ebola infection.
Research published in Cell Host and Microbe reveals a minor reduction in CD45 levels provides protection against both Ebola virus and Bacillus anthracis. Mice expressing reduced CD45 levels showed enhanced viral clearance and increased protection against infection.
Scientists discovered two critical biochemical pathways for Ebola virus entry into cells and developed inhibitors to block them. The UTMB team prevented Ebola infection in cell culture experiments, a crucial step towards developing the first therapy for the deadly disease.
Researchers at University of Pennsylvania School of Medicine discovered that Ebola virus disables tetherin protein to prevent its inhibition, allowing the virus to spread. Understanding this mechanism may facilitate the development of therapeutics to slow down viral replication.
Researchers have solved the structure of VP35, a key part of the Ebola protein that interferes with host cell defense mechanisms. This discovery paves the way for designing drugs that can bind to and inhibit VP35 function, potentially neutralizing the Ebola virus.
The discovery of Bundibugyo ebolavirus represents a significant addition to the puzzle of the Ebola virus genus. The new virus is genetically distinct from all other known Ebola virus species, differing by more than 30% at the genetic level. This finding has implications for the development of diagnostics, antivirals, and vaccines.
Researchers at the University of Texas Medical Branch have discovered a key biochemical link in the process by which Ebola Zaire virus infects cells. By activating the PI3 kinase pathway, Ebola tricks the cell into drawing it into an endosome, where it can reproduce itself.
Researchers describe the shape of the Ebola virus spike protein bound to an immune system antibody, providing a major step forward in understanding how the deadly virus works. The structure reveals vulnerable sites that can be exploited to develop potential Ebola virus vaccines or treatments.
Researchers have successfully tested Ebola vaccines in primates, triggering a cell-mediated response and producing effective protection. The candidates are now set to be tested on humans for the first time, offering hope for controlling outbreaks and protecting healthcare workers.
Researchers at the University of Pennsylvania have identified a protein, ISG15, that slows down the spread of Ebola virus by blocking its ability to escape from cells. This finding offers promise for future treatments against Ebola outbreaks.
A combination vaccine using virus-like particles (VLPs) provides complete protection against Ebola and Marburg viruses in monkeys. This innovative approach has the potential to offer broad-based immunity and is considered a leading candidate for use as a filovirus vaccine in humans.
Researchers from the University of Wisconsin-Madison have developed a system to genetically disarm the Ebola virus by removing its VP30 gene. This allows for safe study of the pathogen in specialized cells, enabling the development of countermeasures such as vaccines and antiviral compounds.
Scientists have identified a new genetic lineage of the Ebola virus in great apes, which contradicts previous assumptions about its evolutionary development. This discovery suggests that wild strains of Ebolavirus can exchange genetic material through recombination processes.
Scientists have found Marburg virus in Egyptian rousette fruit bats, a non-symptom developing carrier species that likely transmits the virus to humans. The discovery reveals this bat as Africa's natural reservoir and highlights the need for public health measures to prevent future outbreaks.
A new study finds that 93% of gorillas at the Lossi Sanctuary in Congo were killed by Ebola during outbreaks in 2002 and 2003. The research suggests that targeted vaccination strategies could be effective in controlling the spread of the disease, which has devastated ape populations in Africa.
Researchers discovered a pattern to Ebola's spread, linking it to wildlife populations and climate. The study found that the virus spreads both within and between species, with outbreaks more frequent than previously believed.
Researchers have identified a key mechanism by which Filoviruses, including Ebola and Marburg, cause immunosuppression. By targeting specific amino acid sequences, new drugs may be developed to disrupt the virus's ability to shut down the immune system.
Researchers studied gorilla population during Ebola outbreak and found transmission between groups led to high mortality rate. The study suggests ape-to-ape transmission plays a significant role in the spread of the virus.
Researchers at Columbia University's Mailman School of Public Health have developed a rapid and highly sensitive diagnostic test for pathogens responsible for disease outbreaks. The new test, known as MassTag PCR, can simultaneously identify multiple agents and reduce the time needed for differential diagnosis.
A Phase 1 trial of an Ebola DNA vaccine demonstrated strong immune responses in all fully vaccinated volunteers. The vaccine, developed by Vical, was well-tolerated and showed effectiveness against Ebola-specific antibodies.
Researchers used novel antisense drugs to interrupt normal Ebola virus replication, showing protection in non-human primates. The therapy directly targets the virus and may be more potent than current anti-viral treatments.
Researchers analyzed genetic data and outbreak patterns to find that the Zaire strain of Ebola virus is spreading as a wave from its first epidemic in Yambuku, Gabon. This suggests that the virus may reach populated areas within 1-2 years and devastated gorilla populations in 3-6 years.
Researchers have developed a new vaccine that is 100 percent effective in protecting monkeys from infection with deadly viruses Ebola and Marburg. The vaccine targets dendritic cells, which are the same cells attacked by these viruses.
Researchers identified cathepsin B and L as essential enzymes for Ebola virus reproduction, shedding light on its infection mechanism. Inhibiting these enzymes could lead to the development of a broad-spectrum antiviral therapy against multiple hemorrhagic fever viruses.
Researchers found that 12.9% of wild chimpanzees carry Ebola virus antibodies, indicating regular contact with the animal reservoir and non-fatal infections. Dogs also carry the virus, with high antibody prevalence near epidemic foci, suggesting they could become a potential source of infection for humans.
Research reveals that Ebola viruses can spread from wild animals to humans through handling or consuming animal carcasses. This finding emphasizes the need for improved awareness and monitoring of wildlife in Central Africa to prevent future outbreaks.
A possible new Ebola outbreak could lead to the deaths of over 20,000 western lowland gorillas within months if confirmed. The park is home to an estimated 30,000 gorillas, and a study suggests that when Ebola affects an area, more than 80% of great apes die from the disease.
A study by Wildlife Conservation Society reveals that simultaneous Ebola outbreaks consist of multiple viral strains originating from different areas. The authors recommend establishing a monitoring network to look for dead and dying large animals as an early warning system to minimize damage to both people and wildlife.
The Ebola virus has unleashed several lethal epidemics in Central Africa, leading to haemorrhagic fever and high mortality rates. The virus is transmitted by direct contact with infected animals or their carcasses, resulting in a rapid decline in great ape populations.
Researchers have discovered a potential treatment for Ebola, showing a 33% survival rate among treated macaques. The study found that inhibiting blood coagulation pathways prolonged survival time and improved health outcomes.
A new drug, rNAPC2, has shown promising results in treating Ebola by slowing coagulopathy and death in primates. The treatment targets the disease process rather than replicating the virus, offering a potential breakthrough in combating the deadly disease.
Researchers at USAMRIID have developed Ebola virus-like particles (VLPs) that induce both cell-mediated and humoral immunity in mice, providing 100% protection against lethal challenge. The VLPs, resembling infectious viral particles without genetic material, offer a promising vaccine platform for Ebola and other viruses.
The first human trial of a DNA Ebola vaccine opened at the NIH Clinical Center in Bethesda. Twenty-seven volunteers will receive either the investigational vaccine or a placebo injection over two months and be followed for one year.
Scientists at NIAID and USAMRIID developed a prime-boost vaccine strategy that protects monkeys from Ebola infection. The boost alone shows promise in offering quick but weaker immune response.
Scientists create hybrid virus that can attach to lung cells' top surface, allowing healthy genes to enter and correct genetic defects associated with cystic fibrosis. The new approach increases production of viral particles, a crucial step towards preclinical studies.
A recent study warns of a dramatic decline in western equatorial Africa's great ape populations, with gorillas and chimpanzees facing nearly 60% decline since 1983. The research highlights the urgent need for aggressive investments in Ebola prevention, law enforcement, and protected area management to ensure their survival.
A study published in Nature reveals that wild chimpanzee and gorilla populations have declined by over 50% in the past few decades, with an estimated 80% decline expected within 30 years. The researchers attribute this to illegal hunting and Ebola outbreaks, highlighting the need for improved anti-poaching laws and Ebola research.
Researchers discover protein from blue-green algae that inhibits both HIV and Ebola virus infections, potentially leading to new treatments. The protein works by binding to the outside of the viruses and blocking them from entering cells.
Researchers found a biochemical structure similarity between the Ebola virus outer protein shell and retroviruses carried by birds, suggesting possible bird transmission. This discovery raises health concerns for humans and encourages officials to be vigilant.
Researchers at Purdue University have simplified the outer shell of the Ebola virus, making it easier to produce in a lab and delivering genes to defective cells. This breakthrough could lead to treatments for diseases like cystic fibrosis and lung cancer.
Hemorrhagic fever viruses, such as Ebola and Marburg, pose significant threats due to their high mortality rates and lack of effective treatments. The report recommends improving diagnostic capacity, developing rapid tests, and researching new antiviral medications to counter these threats.
Researchers mapped areas of Africa at risk for RVF outbreaks, identifying conditions necessary for breeding mosquitoes that transmit the virus. Satellite data also suggested a link between dry to wet changes in tropical regions and Ebola outbreaks.
Gladstone researchers identified a key protein on cells that can be targeted to block Ebola and Marburg virus entry. This finding offers new hope for developing treatments against these deadly viruses.
Researchers at the University of Pennsylvania have discovered a key protein, VP40, crucial for Ebola's replication cycle. This finding holds promise for developing novel antiviral drugs to stop the spread of the deadly disease.
A team of researchers at NIH has developed a novel vaccine that prevents Ebola virus infection in monkeys, offering a promising new approach to protecting humans. The vaccine induces strong anti-Ebola immune responses and protects against lethal doses of the virus.
Researchers have identified a viral protein responsible for Ebola-induced internal bleeding. The discovery could lead to the development of targeted antiviral treatments and vaccines to prevent the disease. By understanding how the virus attaches to and enters cells, scientists can design more effective countermeasures.